This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jonathan K. Wilkin, MD
Director, Division of Dermatologic and Dental Drug Products Center for Drug Evaluation and Research US Food and Drug Administration HFD-540 5600 Fishers Ln Rockville, MD 20857

Arch Dermatol. 1997;133(2):243-244.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The article by Brodell¹ on micromanaged care in a recent issue of the ARCHIVES contained several disconcerting revelations about managed care guidelines that may undermine the safety of a drug frequently prescribed by dermatologists: Accutane (Roche Laboratories, Nutley, NJ) (isotretinoin). Isotretinoin is effective in treating acne, but it is also teratogenic. The manufacturer, in conjunction with the Food and Drug Administration and with input from the Dermatologic Drugs Advisory Committee, implemented a multicomponent program designed to reduce the risk of pregnancy among women prescribed Accutane.²

The Pregnancy Prevention Program is supported by materials distributed to all dermatologists and to those nondermatologists who are recognized prescribers of Accutane.³ The Accutane package insert provides the informational elements on which this program is based. Special problems, particularly those that may lead to death or serious injury, may be required by the Food and Drug Administration to be placed . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?